GlassScriptPhysician profile
Nicholas A Williams
NPI 1982014049
$2,909.61
in general payments reported to CMS, 2019-2025
35 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $605 · 2022: $1,016 · 2023: $281 · 2024: $365 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $377.51 | 2022-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $363.45 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $312.11 | 2021-2025 | |
| Lilly USA, LLC | $254.64 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $182.71 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Vistapharm, INC. | $113.92 | 2021 | |
| Novo Nordisk INC | $107.06 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $99.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $92.96 | 2021-2022 | |
| Horizon Therapeutics Plc | $92.39 | 2021-2023 | Tepezza |
| Tandem Diabetes Care, INC. | $81.55 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $72.54 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $66.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.18 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $55.60 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.66 | 2022 | |
| Beta Bionics, INC. | $51.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $47.91 | 2022-2025 | Omnipod |
| Astellas Pharma US INC | $38.15 | 2023-2024 | Veozah |
| Dexcom, INC. | $35.79 | 2021-2022 | |
| Ibsa Pharma INC. | $35.49 | 2021 | |
| Madrigal Pharmaceuticals | $33.51 | 2025 | Rezdiffra |
| Kowa Pharmaceuticals America, INC. | $27.84 | 2021 | |
| Phathom Pharmaceuticals, INC. | $26.93 | 2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $24.36 | 2025 | Horizant |
| Pfizer INC. | $22.92 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.65 | 2024 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $22.59 | 2025 | |
| Glaxosmithkline, LLC. | $21.88 | 2025 | Bexsero, Pediarix |
| Mannkind Corporation | $21.58 | 2022 | |
| Corcept Therapeutics | $19.59 | 2022 | |
| Recordati_rare_diseases_inc. | $18.91 | 2021 | |
| Esperion Therapeutics, INC. | $17.70 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.